SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of QIAGEN N.V. (NYSE – QGEN)

BALA CYNWYD – October 22, 2026 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Supervisory Board and Managing Board of QIAGEN N.V. (“QIAGEN” or the “Company”) (NYSE – QGEN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Crown NL Bidco B.V., an entity controlled by EQT Private Equity, for €46.50 (@$52.22 at current exchange rates) per share in cash. The transaction values QIAGEN at approximately $12.1 billion in enterprise value at current exchange rates, including approximately $1.1 billion of net debt.

The investigation concerns whether the QIAGEN Boards breached their fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

If you own shares of QIAGEN stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders.

Attorney advertising. Prior results do not guarantee a similar outcome.